FDA Approves Terlipressin for the Management of HRS-1: Approval followed resubmission of data from the phase 3 CONFIRM trial to the agency

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drug topics 2023-01, Vol.167 (1), p.33
1. Verfasser:	Doyno, Cassandra
Format:	Magazinearticle
Sprache:	eng
Schlagworte:	Drug approval Drug therapy Methods Multiple organ failure
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue	1
container_start_page	33
container_title	Drug topics
container_volume	167
creator	Doyno, Cassandra
description
format	Magazinearticle
fullrecord	<record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A735404412</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A735404412</galeid><sourcerecordid>A735404412</sourcerecordid><originalsourceid>FETCH-LOGICAL-g206t-ac453706d38cd8971d3558e445805e0c0b103a54bd37345f336e079de23abc9b3</originalsourceid><addsrcrecordid>eNptkFFLwzAQx_ug4Jx-h4DgWyVtkrbzrUznBpuDOZ9HmlzXSNqUJFP2FfzUxrmHCeMeDu5-vz_HXUQDjJM0zrIku4qunfvAGNOM5YPoe_JUorLvrfkEh9ZgteotOKc6VBuLfANowTu-hRY6j0yNpqu3OHk8KlwHSmvzBRIFa1e1Kqim-wUl9xzV1rSHkL7hDhBB4-XrZLZaIG9VkL05LEN8J_Y30WXNtYPbYx9G75Pn9Xgaz5cvs3E5j7cpznzMBWUkx5kkhZDFKE8kYawASlmBGWCBqwQTzmglSU4oqwnJAOcjCSnhlRhVZBjd_eVuuYaN6mrjLRfhcrEpc8IopjRJAxWfocKhYLk2HdQqjP_xD2f4UBJaJc4K9ydCA1z7xhm98-F_7hT8AZ_qiIE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>magazinearticle</recordtype></control><display><type>magazinearticle</type><title>FDA Approves Terlipressin for the Management of HRS-1: Approval followed resubmission of data from the phase 3 CONFIRM trial to the agency</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Doyno, Cassandra</creator><creatorcontrib>Doyno, Cassandra</creatorcontrib><identifier>ISSN: 0012-6616</identifier><language>eng</language><publisher>Intellisphere, LLC</publisher><subject>Drug approval ; Drug therapy ; Methods ; Multiple organ failure</subject><ispartof>Drug topics, 2023-01, Vol.167 (1), p.33</ispartof><rights>COPYRIGHT 2023 Intellisphere, LLC</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>780,784</link.rule.ids></links><search><creatorcontrib>Doyno, Cassandra</creatorcontrib><title>FDA Approves Terlipressin for the Management of HRS-1: Approval followed resubmission of data from the phase 3 CONFIRM trial to the agency</title><title>Drug topics</title><subject>Drug approval</subject><subject>Drug therapy</subject><subject>Methods</subject><subject>Multiple organ failure</subject><issn>0012-6616</issn><fulltext>true</fulltext><rsrctype>magazinearticle</rsrctype><creationdate>2023</creationdate><recordtype>magazinearticle</recordtype><sourceid/><recordid>eNptkFFLwzAQx_ug4Jx-h4DgWyVtkrbzrUznBpuDOZ9HmlzXSNqUJFP2FfzUxrmHCeMeDu5-vz_HXUQDjJM0zrIku4qunfvAGNOM5YPoe_JUorLvrfkEh9ZgteotOKc6VBuLfANowTu-hRY6j0yNpqu3OHk8KlwHSmvzBRIFa1e1Kqim-wUl9xzV1rSHkL7hDhBB4-XrZLZaIG9VkL05LEN8J_Y30WXNtYPbYx9G75Pn9Xgaz5cvs3E5j7cpznzMBWUkx5kkhZDFKE8kYawASlmBGWCBqwQTzmglSU4oqwnJAOcjCSnhlRhVZBjd_eVuuYaN6mrjLRfhcrEpc8IopjRJAxWfocKhYLk2HdQqjP_xD2f4UBJaJc4K9ydCA1z7xhm98-F_7hT8AZ_qiIE</recordid><startdate>20230101</startdate><enddate>20230101</enddate><creator>Doyno, Cassandra</creator><general>Intellisphere, LLC</general><scope/></search><sort><creationdate>20230101</creationdate><title>FDA Approves Terlipressin for the Management of HRS-1: Approval followed resubmission of data from the phase 3 CONFIRM trial to the agency</title><author>Doyno, Cassandra</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g206t-ac453706d38cd8971d3558e445805e0c0b103a54bd37345f336e079de23abc9b3</frbrgroupid><rsrctype>magazinearticle</rsrctype><prefilter>magazinearticle</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Drug approval</topic><topic>Drug therapy</topic><topic>Methods</topic><topic>Multiple organ failure</topic><toplevel>online_resources</toplevel><creatorcontrib>Doyno, Cassandra</creatorcontrib><jtitle>Drug topics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Doyno, Cassandra</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>FDA Approves Terlipressin for the Management of HRS-1: Approval followed resubmission of data from the phase 3 CONFIRM trial to the agency</atitle><jtitle>Drug topics</jtitle><date>2023-01-01</date><risdate>2023</risdate><volume>167</volume><issue>1</issue><spage>33</spage><pages>33-</pages><issn>0012-6616</issn><pub>Intellisphere, LLC</pub></addata></record>
fulltext	fulltext
identifier	ISSN: 0012-6616
ispartof	Drug topics, 2023-01, Vol.167 (1), p.33
issn	0012-6616
language	eng
recordid	cdi_gale_infotracmisc_A735404412
source	EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects	Drug approval Drug therapy Methods Multiple organ failure
title	FDA Approves Terlipressin for the Management of HRS-1: Approval followed resubmission of data from the phase 3 CONFIRM trial to the agency
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T16%3A03%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=FDA%20Approves%20Terlipressin%20for%20the%20Management%20of%20HRS-1:%20Approval%20followed%20resubmission%20of%20data%20from%20the%20phase%203%20CONFIRM%20trial%20to%20the%20agency&rft.jtitle=Drug%20topics&rft.au=Doyno,%20Cassandra&rft.date=2023-01-01&rft.volume=167&rft.issue=1&rft.spage=33&rft.pages=33-&rft.issn=0012-6616&rft_id=info:doi/&rft_dat=%3Cgale%3EA735404412%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A735404412&rfr_iscdi=true